| Name | [(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1,2,4-triazol-1-yl)butan-2-yl]oxymethyl dihydrogen phosphate |
|---|---|
| Synonyms |
Benzonitrile,4-(2-((1R,2R)-2-(2,4-difluorophenyl)-1-methyl-2-((phosphonooxy)methoxy)-3-(1H-1,2,4-triazol-1-yl)propyl)-4-thiazolyl)
UNII-L4Q6O5430L |
| Description | Fosravuconazole is a prodrug of ravuconazole, with antifungal activity. |
|---|---|
| Related Catalog | |
| Target |
Fungal[1] |
| In Vitro | Fosravuconazole (BMS-379224) is a prodrug of ravuconazole, with antifungal activity[1]. |
| In Vivo | Fosravuconazole (BMS-379224) is rapidly conversed to ravuconazole upon iv administration to rats. Fosravuconazole shows comparable efficacy at inhibiting C. albicans infection model in mice as orally administered ravuconazole[1]. |
| References |
| Molecular Formula | C23H20F2N5O5PS |
|---|---|
| Molecular Weight | 547.47100 |
| Exact Mass | 547.08900 |
| PSA | 181.43000 |
| LogP | 4.33408 |